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Editorial on the Research Topic
Bacteriocins and Other Ribosomally Synthesised and Post-translationally Modified Peptides
(RiPPs) as Alternatives to Antibiotics
This Research Topic concerns bacteriocins and others RiPPs (Ribosomally synthesized and
Post-translationally modified Peptides) as alternatives to antibiotics. Due to the increasing problem
of antibiotic resistance globally, there is a pressing need to source such alternative antimicrobials.
Here, in this editorial, we summarize the key papers that were published as part of this Research
Topic, which consisted of a diverse range of research as well as review articles, pertaining to several
different bacteriocins and RiPPs.
A number of these studies report the discovery of novel bacteriocins or RiPPs, either through
in silico genome mining approaches, laboratory experimental-based approaches or a combination
thereof. In one such study, using a combination of lab-based and in silico approaches, Angelopoulou
et al. reported the discovery of a range of bacteriocins synthesized by strains isolated from human
milk. More specifically, the authors isolated bacteriocin producers from 37 human milk samples
and found 73 putative bacteriocin gene clusters, which included 16 completely novel prepeptides.
Amongst the key findings of the study were the discovery of 2 novel lantibiotics, 3 class IIa
bacteriocins, 4 sactibiotics, 1 novel class IIb bacteriocin, 4 new class IIc, and 2 class IId bacteriocins,
highlighting that the human milk microbiota is a potentially rich source of diverse antimicrobials.
In a separate in silico study, Sabino et al. found that ruminal bacteria are a potentially rich source
of lasso peptides. More specifically, a genome mining approach was employed by the authors,
using tools such as BAGEL4 and antiSMASH5 to screen 425 bacterial genomes from the rumen
ecosystem for lasso peptide production. Overall, Sabino et al. found 23 incomplete and 11 complete
putative lasso peptide gene clusters amongst the genomes analyzed. Finally, a study by Zendo et al.
reported the discovery of a novel nisin variant, kunkecin A, synthesized by Apilactobacillus kunkeei
FF30-6, a lactic acid bacterium isolated from honey bees. The study describes its antimicrobial
activity against Melissococcus plutonius, one of the major bacterial pathogens of honeybee broods.
Furthermore, the genome sequence of A. kunkeei FF30-6 revealed that the biosynthetic machinery
of the novel bacteriocin resides in the plasmid pKUNFF30-6. A more in-depth analysis of the
kunkecin A gene cluster also revealed that it is quite distinct from the nisin A gene cluster, and
is devoid of genes corresponding to nisR, nisK, and nisI. However, both nisin A and kunkecin A are
likely to share similar post-translational modification processes. The structure of kunkecin A was
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also proposed in the study, on the basis of observed and
calculated molecular masses of the peptide. Together, these
studies emphasize the growing importance of sequence mining
approaches in the discovery of novel RiPPs.
A few studies as part of this Research Topic report the
investigation of the activities of nisin variants and/or semi-
synthetic hybrids of nisin. In one such interesting study, Reiners
et al. provided insights into the antimicrobial activity of nisin
H, a natural variant of nisin, in addition to the nisin H F1I
derivative. The authors expressed the peptide in a heterologous
host and determined the yield, the cleavage efficiency using
NisP as well as effects on the post-translational modification
using mass spectrometry techniques. In addition, the authors
determined the effects of nisin H and nisin H F1I on the activity
of NisI and NisFEG responsible for nisin immunity, as well as the
resistance determinants SaNSR and SaNsrFP from Streptococcus
agalactiae. Overall, the authors found that nisin H and nisin
H F1I were more potent than nisin A when tested against
clinical isolates of Enterococcus faecalis, Enterococcus faecium and
Staphylococcus aureus. In a separate study, Deng et al. reported
that biologically active and stable forms of nisin are generated
upon conjugation of synthetic hydrophobic polyproline moieties
to the lipid II binding fragments of the nisin peptide. The
authors used click chemistry technology to conjugate moieties
of synthetic polyproline to either nisin AB (encompassing rings
A and B of nisin) or to nisin ABC (encompassing rings A,
B, and C of nisin). Importantly, the authors found that the
conjugation of the synthetic polyproline O63K with nisin ABC
resulted in a 16-fold increase in bioactivity, compared to nisin
ABC, highlighting the potential of semi-synthetic nisin hybrids
as novel antimicrobials. Furthermore, such nisin ABC hydrids
are recalcitrant to degradation by nisinase and other proteolytic
enzymes at the C-terminus of nisin. These semi-synthetic
hybrids, which maintain potent or enhanced antimicrobial
activity, could present viable means to circumvent certain nisin
resistance mechanisms. Albeit resistance to bacteriocins has been
described in several studies over the years, such instances have
mainly related to resistance demonstrated in in vitro studies
rather than in clinical settings/food systems. Thus, bacteriocins
may present viable alternatives used in clinical settings, especially
in light of the widespread reports of antibiotic resistance globally.
In this regard, the use of semisynthetic derivatives of lantibiotics
such as nisin and other such hybrid compounds and/or non-
ribosomally synthesized peptides, such as those described above,
may be a possible means to circumvent issues relating to
antibiotic resistance in the clinic. By gaining insights into
the precise mode of action of different bacteriocins against
specific clinical pathogens, the use of such hydrid compounds
could be particularly important as a means to tailor-make
narrow spectrum antimicrobials with a view to targeting specific
pathogens in the clinic, whilst minimizing the impact on the
overall host microbiome.
In relation to class II bacteriocins, a very interesting study
by Ross et al. reported the design of synthetic peptide libraries
derived from a minimal alpha helical domain of enterocin AS-
48 homologs and antimicrobial activities thereof. The alpha
helical region of this circular bacteriocin enterocin AS-48 is
chiefly responsible for its membrane-permeating and resultant
antibacterial activity. The authors conducted homology-based
searches of similar domains in several bacterial genomes, used
these alpha helical domains as scaffolds to design minimal
peptide libraries and assessed their antimicrobial activity. An
impressive total of 384 synthetic peptides were evaluated for
antimicrobial activity in the study and the authors found that
MICs in the low nanomolar range were obtained for the most
potent peptides, with no concomitant cytotoxic effects. Thus,
studies like this present a blueprint or scaffold for the rational
design of semi-synthetic bacteriocin peptide libraries for further
evaluation. In a separate study, Vermeulen et al. described the
expression of plantaricin 423 and mundticin ST4SA, both class
IIa bacteriocins in E. coli as a heterologous host, using Green
Fluorescent Protein as a fusion partner. Importantly, the authors
reported that His-tagged GFP fusion proteins encompassing
these bacteriocins, in addition to being autofluorescent, overcame
the issue of inclusion body formation, and also decreased the
toxicity of these bacteriocins during heterologous expression.
The autofluorescence also facilitated real-time quantification of
protein yields during heterologous expression.
With regards to studies focused on the potential for
bacteriocin resistance development, an interesting study by
Campelo et al. reported that a Bce-like bacitracin resistance
module in Lactococcus lactis is activated upon exposure to
the bacteriocin Lcn972. A further possible concern in this
regard is that general MFS transporters may contribute to
multidrug resistance in pathogenic bacteria, which may also
include resistance to bacteriocins. These types of studies are
extremely important as they highlight the potential downsides
of utilizing bacteriocins, as in certain cases, resistance to other
antimicrobials may inadvertently be enhanced as well. YsaDCB
is a L. lactis ABC transporter that along with TCS-G, forms a
detoxification module conferring protection against the cell wall
biosynthesis inhibitors bacitracin and the bacteriocin Lcn972.
By using a combination of heterologous expression and RT-
qPCR, the authors elucidated the precise function of the ysaDCB
operon. Overall, the authors found that ysaB encodes a putative
Bce-like permease, whilst ysaD encodes a secreted peptide
which is likely to be associated with signal relay between
the YsaDCB ABC transporter and TCS-G and are together
involved in largely similar but somewhat distinct mechanisms
of resistance to bacitracin and Lcn972. Telhig et al. published
an interesting review article relating to the use of bacteriocins
to attenuate antimicrobial resistance in Gram negative bacteria.
More specifically, the authors describe the potential use of
unmodified and modified microcins, including lasso peptides,
nucleotide peptide, siderophore peptides, and linear azole(in)e-
containing peptides as a means to decrease the likelihood of
antimicrobial resistance amongst Gram negative bacteria. In
addition, the review described the potential of the development
of cross-resistance and co-resistance in Gram negative bacteria,
to various antibiotics and microcins.
Finally, a number of review articles covering a range of topics
pertaining to bacteriocins and other RiPPs were published as
part of this Research Topic. A very interesting review article
by Karbalaei-Heidari and Budisa highlighted the potential of
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utilizing genetic code expansion strategies in lanthipeptides with
a view to attenuating the likelihood of the development of
antimicrobial resistance to lanthipeptides. This is because the
conventional genetic code and protein engineering strategies
are limited to merely 20 canonical amino acids. However, the
authors in this review highlight the prospective use of non-
canonical amino acids during protein translation with a view
to forming semi-synthetic lantibiotics with enhanced biological
and chemical properties compared to their natural variants.
Another interesting review by Lagedroste et al. summarized
recent studies investigating the precise roles and mechanisms of
action of enzymes involved in the post-translational modification
processes of lanthipeptides. Finally, a review by Rooney et al.
summarized the potential of bacteriocins as “plantibiotics of
the future” by reporting the details of recent studies of the
antimicrobial activity of bacteriocins against Gram-negative
phytopathogenic bacteria. It must be noted however that
much remains to be elucidated with regards to the impact
that extraneous factors such as solar radiation, alterations in
light intensity, humidity and temperature have on the stability
and antimicrobial activity of bacteriocins and non-ribosomal
peptides when potentially being used as antimicrobial agents to
control plant infections.
In conclusion, this Research Topic has significantly added
to the field of research relating to bacteriocins and RiPPs by
highlighting the role of new approaches like in silico mining
and RiPP engineering, but also addressing some of the potential
issues faced by those wishing to commercialize RiPPs for clinical,
agricultural, or industrial use.
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